5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
5-MeO-DMT
anxiety
depression
psychedelic
tryptamine
Journal
The American journal of drug and alcohol abuse
ISSN: 1097-9891
Titre abrégé: Am J Drug Alcohol Abuse
Pays: England
ID NLM: 7502510
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
2
3
2019
medline:
1
4
2020
entrez:
2
3
2019
Statut:
ppublish
Résumé
A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. We examined self-reported improvement in depression and anxiety among people who use 5-MeO-DMT in a group setting with structured procedures guiding dose and administration of 5-MeO-DMT. Such procedures also include activities for the preparation of, and support during/following sessions, which are similar to procedures used in clinical trials of hallucinogen administration. Next, we examined whether depression or anxiety were improved following use, and whether the acute subjective effects (mystical/challenging) or beliefs about the 5-MeO-DMT experience were associated with improvements in these conditions. Respondents (n = 362; M Of those reporting having been diagnosed with depression (41%) or anxiety (48%), most reported these conditions were improved (depression = 80%; anxiety = 79%) following 5-MeO-DMT use, and fewer reported they were unchanged (depression = 17%; anxiety = 19%) or worsened (depression = 3%; anxiety = 2%). Improvement in depression/anxiety conditions were associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning of the 5-MeO-DMT experience. There were no associations between depression or anxiety improvement and the intensity of acute challenging physical/psychological effects during the 5-MeO-DMT experience. Future prospective controlled clinical pharmacology studies should examine the safety and efficacy of 5-MeO-DMT administration for relieving depression and anxiety.
Sections du résumé
BACKGROUND
A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials.
OBJECTIVES
We examined self-reported improvement in depression and anxiety among people who use 5-MeO-DMT in a group setting with structured procedures guiding dose and administration of 5-MeO-DMT. Such procedures also include activities for the preparation of, and support during/following sessions, which are similar to procedures used in clinical trials of hallucinogen administration. Next, we examined whether depression or anxiety were improved following use, and whether the acute subjective effects (mystical/challenging) or beliefs about the 5-MeO-DMT experience were associated with improvements in these conditions.
METHODS
Respondents (n = 362; M
RESULTS
Of those reporting having been diagnosed with depression (41%) or anxiety (48%), most reported these conditions were improved (depression = 80%; anxiety = 79%) following 5-MeO-DMT use, and fewer reported they were unchanged (depression = 17%; anxiety = 19%) or worsened (depression = 3%; anxiety = 2%). Improvement in depression/anxiety conditions were associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning of the 5-MeO-DMT experience. There were no associations between depression or anxiety improvement and the intensity of acute challenging physical/psychological effects during the 5-MeO-DMT experience.
CONCLUSIONS
Future prospective controlled clinical pharmacology studies should examine the safety and efficacy of 5-MeO-DMT administration for relieving depression and anxiety.
Identifiants
pubmed: 30822141
doi: 10.1080/00952990.2018.1545024
pmc: PMC6430661
mid: NIHMS996107
doi:
Substances chimiques
Hallucinogens
0
Methoxydimethyltryptamines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-169Subventions
Organisme : NIDA NIH HHS
ID : R01 DA003889
Pays : United States
Organisme : NIAAA NIH HHS
ID : T32 AA007477
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007209
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Can J Psychiatry. 2010 Mar;55(3):126-35
pubmed: 20370962
Front Pharmacol. 2018 Jan 17;8:974
pubmed: 29387009
Curr Drug Abuse Rev. 2014;7(3):157-64
pubmed: 25563443
World Psychiatry. 2014 Feb;13(1):56-67
pubmed: 24497254
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92
pubmed: 16826400
Lancet Psychiatry. 2016 Jul;3(7):619-27
pubmed: 27210031
Neurotherapeutics. 2017 Jul;14(3):734-740
pubmed: 28585222
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
J Psychopharmacol. 2018 Jul;32(7):779-792
pubmed: 29708042
Psychol Med. 2011 Nov;41(11):2239-52
pubmed: 21672297
Depress Anxiety. 2010;27(1):78-89
pubmed: 19569060
J Psychosom Res. 2015 Feb;78(2):109-15
pubmed: 25510186
Clin Psychol Rev. 2004 Sep;24(5):583-616
pubmed: 15325746
Clin Psychol Rev. 2015 Aug;40:91-110
pubmed: 26094079
J Psychopharmacol. 2016 Dec;30(12):1268-1278
pubmed: 27578767
J Psychopharmacol. 2008 Aug;22(6):621-32
pubmed: 18593735
Dialogues Clin Neurosci. 2015 Sep;17(3):327-35
pubmed: 26487813
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
Psychopharmacology (Berl). 2011 Dec;218(4):649-65
pubmed: 21674151
Dialogues Clin Neurosci. 2011;13(4):423-37
pubmed: 22275848
J Psychoactive Drugs. 2001 Oct-Dec;33(4):403-7
pubmed: 11824699
J Psychopharmacol. 2015 Nov;29(11):1182-90
pubmed: 26442957
PeerJ. 2017 Jul 7;5:e3544
pubmed: 28698825
Fed Regist. 2010 Dec 20;75(243):79296-300
pubmed: 21171485
J Psychopharmacol. 2011 Nov;25(11):1562-7
pubmed: 20395317
Psychopharmacology (Berl). 2018 Feb;235(2):459-466
pubmed: 29085980
Dialogues Clin Neurosci. 2011;13(1):7-23
pubmed: 21485743
BMJ. 1998 Apr 18;316(7139):1236-8
pubmed: 9553006
Cognit Ther Res. 2012 Oct 1;36(5):427-440
pubmed: 23459093
Int J Epidemiol. 2014 Apr;43(2):476-93
pubmed: 24648481
J Sci Study Relig. 2012 Dec;51(4):721-737
pubmed: 23316089
Arch Toxicol. 2015 Aug;89(8):1151-73
pubmed: 25877327
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
J Psychopharmacol. 2016 Dec;30(12):1279-1295
pubmed: 27856683
Sci Rep. 2017 Oct 13;7(1):13187
pubmed: 29030624